EA201000251A1 - Фармацевтический препарат для пролонгированного высвобождения - Google Patents

Фармацевтический препарат для пролонгированного высвобождения

Info

Publication number
EA201000251A1
EA201000251A1 EA201000251A EA201000251A EA201000251A1 EA 201000251 A1 EA201000251 A1 EA 201000251A1 EA 201000251 A EA201000251 A EA 201000251A EA 201000251 A EA201000251 A EA 201000251A EA 201000251 A1 EA201000251 A1 EA 201000251A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pharmaceutical preparation
pharmaceutically acceptable
acid salt
prolonged delivery
arstvennym
Prior art date
Application number
EA201000251A
Other languages
English (en)
Inventor
Бертиль Свен Инге Абрахамссон
Сусанна Йоханна Абрамсен Алами
Хокан Ларс Баггер-Йергенсен
Мария Кристина Синдебю Кулльберг
Ларс Йохан Понтус Де Вердье Йертстам
Сусанна Анетта Нильссон
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201000251A1 publication Critical patent/EA201000251A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Фармацевтический препарат с пролонгированным высвобождением, содержащий в качестве активного ингредиента соединение Ph(3-Cl)(5-OCHF)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) или его фармацевтически приемлемую соль (такую как соль сульфоновой кислоты, такую как соль бензолсульфоновой кислоты (безилат)) и фармацевтически приемлемый разбавитель или носитель, для использования в обеспечении терапевтического антитромботического действия при ограничении межлекарственных взаимодействий с другим(и) одновременно вводимым(и) лекарственным(и) средством(ами), в частности лекарственным(и) средством(ами), которое(ые) подвергается(ются) метаболизму под действием ферментов CYP-450 (цитохром Р-450).
EA201000251A 2007-08-31 2008-08-29 Фармацевтический препарат для пролонгированного высвобождения EA201000251A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96918807P 2007-08-31 2007-08-31
PCT/GB2008/050755 WO2009027745A1 (en) 2007-08-31 2008-08-29 Pharmaceutical formulation for extended release

Publications (1)

Publication Number Publication Date
EA201000251A1 true EA201000251A1 (ru) 2010-08-30

Family

ID=39929593

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000251A EA201000251A1 (ru) 2007-08-31 2008-08-29 Фармацевтический препарат для пролонгированного высвобождения

Country Status (12)

Country Link
US (1) US20090061000A1 (ru)
EP (1) EP2203157A1 (ru)
JP (1) JP2010537966A (ru)
KR (1) KR20100063068A (ru)
CN (1) CN101784264A (ru)
AU (1) AU2008291920A1 (ru)
BR (1) BRPI0815893A2 (ru)
CA (1) CA2696870A1 (ru)
EA (1) EA201000251A1 (ru)
MX (1) MX2010002358A (ru)
WO (1) WO2009027745A1 (ru)
ZA (1) ZA201001127B (ru)

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
IT1229491B (it) * 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
SE9301912D0 (sv) * 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
AU1025795A (en) * 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) * 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
CN1198839C (zh) * 1995-02-17 2005-04-27 艾伯特有限及两合公司 作为凝血酶抑制剂的新的二肽脒类
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
SE9602263D0 (sv) * 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
US5863929A (en) * 1996-06-25 1999-01-26 Eli Lilly And Company Anticoagulant agents
SE9602646D0 (sv) * 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) * 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
SE9704543D0 (sv) * 1997-12-05 1997-12-05 Astra Ab New compounds
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9804313D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New compounds
ES2295004T3 (es) * 1999-01-13 2008-04-16 Astrazeneca Ab Nuevos derivados amidinobencilaminicos y su uso como inhibidores de trombina.
SE9902550D0 (sv) * 1999-07-02 1999-07-02 Astra Ab New crystalline forms
SE0001803D0 (sv) * 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) * 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
SE0102921D0 (sv) * 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
US6811794B2 (en) * 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) * 2003-11-28 2003-11-28 Astrazeneca Ab New process
GB0503672D0 (en) * 2005-02-23 2005-03-30 Astrazeneca Ab New process
GB0510546D0 (en) * 2005-05-24 2005-06-29 Astrazeneca Ab New process
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
BRPI0815893A2 (pt) 2017-05-30
CN101784264A (zh) 2010-07-21
EP2203157A1 (en) 2010-07-07
US20090061000A1 (en) 2009-03-05
MX2010002358A (es) 2010-03-22
AU2008291920A1 (en) 2009-03-05
KR20100063068A (ko) 2010-06-10
ZA201001127B (en) 2010-10-27
JP2010537966A (ja) 2010-12-09
CA2696870A1 (en) 2009-03-05
WO2009027745A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
EA201070597A1 (ru) Антибактериальные аналоги аминогликозида
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
EA200870599A1 (ru) Стабильные препараты лаквинимода
TN2010000019A1 (en) Solid preparation comprising alogliptin and metformin hydrochloride
TW200621737A (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
TW200640908A (en) Chemical compounds
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
HRP20221304T1 (hr) Kombinacija koja sadrži inhibitor mek i inhibitor b-raf
JP2013542247A5 (ru)
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2010030704A3 (en) Antibacterial aminoglycoside analogs
MX2009010165A (es) Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704.
WO2011044501A3 (en) Antibacterial aminoglycoside analogs
WO2006124413A3 (en) Methods for treating drug resistant cancer
TW200630364A (en) 2-amido-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2010132757A3 (en) Antibacterial aminoglycoside analogs
WO2006041631A3 (en) Novel cyclosporin alkynes and their utility as pharmaceutical agents
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
TW200639156A (en) New compounds
RU2014129508A (ru) Новая комбинация
WO2009032843A3 (en) Deuterated ethambutols and their use
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
AU2010275640A8 (en) Benzoquinolizinium salt derivatives as anticancer agents
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases